$1.82
0.07[4.00%]
At close: Apr 22
$1.82
0[0.00%]
After Hours: 7:05PM EDT
Cyclacel Pharmaceuticals
(NASDAQ:CYCC)Cyclacel Pharmaceuticals Stock (NASDAQ:CYCC), Analyst Ratings, Price Targets, Predictions
Cyclacel Pharmaceuticals Inc has a consensus price target of $11.5, established from looking at the 6 latest analyst ratings. The last 3 analyst ratings were released from Brookline Capital, Roth MKM, and Oppenheimer on December 19, 2023, December 19, 2023, and May 25, 2023. With an average price target of $9.67 between Brookline Capital, Roth MKM, and Oppenheimer, there's an implied 431.14% upside for Cyclacel Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Brookline Capital
Roth MKM
Oppenheimer
Oppenheimer
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Cyclacel Pharmaceuticals
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 12/19/2023 | CYCC | Buy Now | Cyclacel Pharmaceuticals | $1.82 | — | Brookline Capital | Kemp Dolliver | — | Downgrade | Buy → Hold | Get Alert |
| 12/19/2023 | CYCC | Buy Now | Cyclacel Pharmaceuticals | $1.82 | 1053.85% | Roth MKM | Jonathan Aschoff | $16 → $21 | Maintains | Buy | Get Alert |
| 05/25/2023 | CYCC | Buy Now | Cyclacel Pharmaceuticals | $1.82 | 339.56% | Oppenheimer | Jeff Jones | → $120 | Maintains | Outperform | Get Alert |
| 03/07/2023 | CYCC | Buy Now | Cyclacel Pharmaceuticals | $1.82 | 339.56% | Oppenheimer | Jeff Jones | $150 → $120 | Maintains | Outperform | Get Alert |
| 07/18/2022 | CYCC | Buy Now | Cyclacel Pharmaceuticals | $1.82 | 834.07% | Oppenheimer | Jeff Jones | → $255 | Assumes | → Outperform | Get Alert |
| 04/30/2021 | CYCC | Buy Now | Cyclacel Pharmaceuticals | $1.82 | 834.07% | Oppenheimer | Kevin DeGeeter | → $255 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Cyclacel Pharmaceuticals (CYCC)?
The latest price target for Cyclacel Pharmaceuticals (NASDAQ: CYCC) was reported by Brookline Capital on December 19, 2023. The analyst firm set a price target for $0.00 expecting CYCC to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cyclacel Pharmaceuticals (CYCC)?
The latest analyst rating for Cyclacel Pharmaceuticals (NASDAQ: CYCC) was provided by Brookline Capital, and Cyclacel Pharmaceuticals downgraded their hold rating.
When was the last upgrade for Cyclacel Pharmaceuticals (CYCC)?
There is no last upgrade for Cyclacel Pharmaceuticals.
When was the last downgrade for Cyclacel Pharmaceuticals (CYCC)?
The last downgrade for Cyclacel Pharmaceuticals Inc happened on December 19, 2023 when Brookline Capital changed their price target from N/A to N/A for Cyclacel Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Cyclacel Pharmaceuticals (CYCC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cyclacel Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cyclacel Pharmaceuticals was filed on December 19, 2023 so you should expect the next rating to be made available sometime around December 19, 2024.
Is the Analyst Rating Cyclacel Pharmaceuticals (CYCC) correct?
While ratings are subjective and will change, the latest Cyclacel Pharmaceuticals (CYCC) rating was a downgraded with a price target of $0.00 to $0.00. The current price Cyclacel Pharmaceuticals (CYCC) is trading at is $1.82, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.